It was reported that the soluble form of ACE2, which acts as a competitive binding partner for SARS-CoV-2, is up-regulated in the peripheral blood of IBD patients and then limits SARS-CoV-2 infection (28, 29). Here, ACE2 is linked to inflammatory bowel disease.